Vitiligo Affects About 2% Globally, Causing Skin Colour Loss

Vitiligo, an autoimmune skin disorder that attacks melanin‑producing cells, affects roughly two percent of people worldwide. The condition can start at any age but is most often noticed in childhood or early adulthood. It appears as white patches where melanocytes are destroyed, and hair in those areas may also turn white. There are two main forms: non‑segmental vitiligo, the common type that produces symmetrical patches on both sides of the body, and segmental vitiligo, which usually begins younger and limits to one side or a single region. Scientists have not pinpointed a single cause, but research shows a mix of genetic susceptibility and immune dysfunction. CD8⁺ cytotoxic T cells mistakenly target melanocytes, leading to depigmentation. Having a relative with vitiligo or another autoimmune disease raises the risk, indicating shared genes. Triggers such as oxidative stress, skin injury or exposure to certain chemicals can aggravate the condition in genetically prone individuals. Vitiligo often co‑exists with other autoimmune disorders, especially autoimmune thyroid disease, prompting doctors to screen thyroid function. Diagnosis commonly uses a Wood’s lamp, which highlights loss of pigment under ultraviolet light. Treatment aims to restore colour or halt spread rather than cure the disease. Options include topical creams to reduce inflammation, narrowband UVB phototherapy, excimer laser or lamp, and short‑term oral medicines. For stable cases, surgical grafting may be considered, while extensive loss of pigment may lead patients to choose depigmentation therapy. ## Context Vitiligo is one of several autoimmune skin conditions, and its link to thyroid disease reflects a broader pattern of immune system overlap. Because the disorder can appear at any age, early detection and regular screening help manage both skin changes and any associated health issues.